This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about Transcription factor SOX-1.
Keeps neural cells undifferentiated by counteracting the activity of proneural proteins and suppresses neuronal differentiation (By similarity). .
Human | |
---|---|
Gene Name: | SOX1 |
Uniprot: | O00570 |
Entrez: | 6656 |
Belongs to: |
---|
No superfamily |
SOX1; SRY (sex determining region Y)-box 1; SRY-related HMG-box gene 1; transcription factor SOX-1
Mass (kDA):
39.023 kDA
Human | |
---|---|
Location: | 13q34 |
Sequence: | 13; NC_000013.11 (112067149..112071706) |
Nucleus.
So what is SOX1 and what can it do? First, let's review the biological significance of SOX1. It's known to be expressed in the CA1 region of the hippocampus, where it inhibits proliferation and PCNA via ERK. However, its function in brain tissue is not well understood. So, what are the best uses for SOX1?
The hippocampal CA1 region expresses Sox1, and so does its homolog, SOX2. Human heterozygous individuals are at higher risk of developing a hippocampus tumor, whereas homozygous mice have a more severe disease. Similarly, homozygous conditional knock-out mutant mice show severe hippocampal and eye defects. Nonetheless, the differential sensitivity of mice to Sox2 dosage is still not understood. In mice, Sox2 pan-neural deletion results in normal hippocampal development, but hypoplastic hippocampus during postnatal life.
Interestingly, early Sox2 mutation reduces the expression of several genes that are crucial for hippocampal development. These genes may be direct targets of SOX2, but the effect is less pronounced than in knockout mice. These genes are required for proper morphogenesis, and their downregulation would explain the failure to form the necessary cell types in the CA1 region.
The expression of SOX1 in the CA1 region of the hunchback is regulated by two transcription factors. One, SOX1, directly binds to the chromatin of some target genes, including Cxcr4. The other, SOX2, binds to distant enhancers in NSC chromatin. The two of them work in concert to control chromatin in the hippocampus.
Sox2 is also expressed in the CA1 region of the gyrus. It was originally detected in CRC precursors but is absent during development. In contrast, Sox1 is expressed in undifferentiated neuroepithelial cells, such as DMS precursors. Upon differentiation, SOX2 expression is silenced. These mutants have a morphologically distinct DG, while FoxG1-Cre mice do not.
The level of SOX1 is also higher in the CA1 region than in the CA3 region of the hippocampus. This difference in the expression pattern of SOX1 is related to the hippocampus' serial pathway of information transfer. However, the difference between control and mutant mice is small. This difference in the amplitude and frequency of EPSCs was not significant.
The expression of SOX1 in the CA1 region of the hivecampus is related to the activity of p53. It has been suggested that chronically high S100B expression may lead to bipolar disorders and other adverse health effects. So, when learning is the primary goal of the cortex, SOX1 is expressed in the CA1 region of the hippocampus.
Although SOX1 is widely expressed in the CA1 region of the hemisphere, the exact role of this protein is not fully understood. However, it may be associated with the activation of the Smad3 transcription factor. In addition to p53 activation, Smad3 also increases the production of S100B. A decrease in the amount of p53 protein indicates activation of p53 negative regulators including ubiquitin ligase Mdm2.
A new RNAi therapy targeting Boster Bio's SOX1 marker has a surprising effect on prostate cancer cells. This drug targets SOX1, which inhibits proliferation through a mechanism known as phosphorylation. When overexpressed in prostate cancer cell lines, SOX1 inhibits proliferation and tumor growth, preventing it from spreading to the liver. Although there are no human studies on the effect of SOX1 on prostate cancer, it can inhibit the progression of the disease.
This inhibitor blocks prostate cancer cell growth by decreasing the phosphorylation of ERK, a key signaling pathway in tumor development. This mechanism has recently been discovered to play a central role in tumor development. In addition to inhibiting proliferation, SOX1 also regulates expression of other proteins, including RAF and MEK. The association between SOX1 and CCA cells was further investigated.
SOX1 is also known to inhibit tumor growth. It inhibits cell proliferation through the Wnt signaling pathway and b-Catenin. It also inhibits the expression of hes1, a downstream target gene of notch2. Moreover, recent studies show that Boster Bio's SOX1 marker suppresses the growth of epithelial ovarian cancer by inhibiting the activity of TRIP13.
SOX1 is a 39-kDa transcription factor belonging to the SRY family of HMG box proteins. It has an extremely conserved high mobility group motif (HMGG) that binds DNA and mediates its binding to transcription. SOX proteins play an important role in embryonic development and regulate stem cells. This makes them valuable markers for the differentiation of particular cell lineages. However, the protein is not found in all mammals.
The RAF/MEK/ERK pathway is a critical signaling pathway for tumor cell survival. Activated RAF can translocate to the cell membrane where it activates downstream MEK and ERK. It also affects gene expression. Sox1 inhibits PCNA by reducing phosphorylation of ERK. In addition, SOX1 decreases ERK phosphorylation in human colon cancer cells, a key marker for cancer progression.
Boster Bio SOX1 inhibits PCN and PCNA by inhibiting RAF/MEK/ERK signaling. Sox1 inhibits PCNA via ERK. This inhibits the growth of tumors and promotes tumor survival. This compound is effective in the treatment of a variety of cancers. It is safe and effective for human use and does not cause any side effects.
In the human population, SOX1 expression levels are low, and ERK phosphorylation decreased. However, the expression of other genes, including b-catenin, HES1, and ERK, was also decreased. Sox1 inhibits PCNA via ERK in mouse tumor cells, but not in human cancer cells. It inhibits the proliferation of tumor cells in vitro and in vivo.
Inhibition of PCNA by SOX1 in mice is an effective cancer treatment. Using mice with TFK-1 and HUCCT-1 cells, the drug inhibits tumor growth. The mice were divided into four groups of five mice for each treatment group. At 18 days post-inoculation, tumors had formed on the right flank. Tumor volumes were measured using digital Vernier calipers. The formula for tumor volume is width x length/2.
PMID: 9337405 by Malas S., et al. Cloning and mapping of the human SOX1: a highly conserved gene expressed in the developing brain.
*More publications can be found for each product on its corresponding product page